Hematologic Oncology

>

Latest News

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.
Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia

June 13th 2025

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.
Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

June 13th 2025

Treatment with cyclosporin/cyclophosphamide following allogeneic stem cell transplant had improved efficacy vs cyclosporin/methotrexate in patients with high-risk hematologic cancers.
Cyclosporin/Cyclophosphamide Is a Potential New SOC in GVHD Management

June 13th 2025

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.
FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications

June 12th 2025

Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings
Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited Settings

June 2nd 2025

Latest CME Events & Activities

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

View More

Go To PER in Chicago

May 30, 2025 - June 3, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

<1
...
5455565758